VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update

VYNE Therapeutics Inc. (NASDAQ:VYNE) saw a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 82,600 shares, an increase of 65.2% from the October 15th total of 50,000 shares. Approximately 0.7% of the company’s stock are sold short. Based on an average trading volume of 70,400 shares, the short-interest ratio is currently 1.2 days.

VYNE Therapeutics Stock Down 0.7 %

Shares of NASDAQ VYNE opened at $3.00 on Wednesday. VYNE Therapeutics has a twelve month low of $1.57 and a twelve month high of $4.48. The firm has a market cap of $44.25 million, a P/E ratio of -3.51 and a beta of 1.32. The company has a 50 day moving average of $2.19 and a 200 day moving average of $2.18.

VYNE Therapeutics (NASDAQ:VYNE) last posted its earnings results on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). VYNE Therapeutics had a negative return on equity of 41.23% and a negative net margin of 6,896.55%. The company had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.11 million. As a group, equities analysts expect that VYNE Therapeutics will post -0.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $5.75 price objective on shares of VYNE Therapeutics in a report on Friday, November 8th.

Institutional Investors Weigh In On VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to the company in its most recent disclosure with the SEC. The fund bought 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics accounts for about 0.0% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 17th largest position. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics at the end of the most recent quarter. 83.78% of the stock is owned by hedge funds and other institutional investors.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.